{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T22:05:17Z","timestamp":1788300317749,"version":"build-2803163510"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,24]],"date-time":"2022-09-24T00:00:00Z","timestamp":1663977600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology Letters"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.imlet.2022.09.004","type":"journal-article","created":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T13:11:49Z","timestamp":1664197909000},"page":"15-22","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Lymphopenic condition enhanced the antitumor immunity of PD-1-knockout T cells mediated by CRISPR\/Cas9 system in malignant melanoma"],"prefix":"10.1016","volume":"250","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1785-8225","authenticated-orcid":false,"given":"Zike","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huita","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shijun","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.imlet.2022.09.004_bib0001","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1182\/blood-2016-09-741629","article-title":"PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy[J]","volume":"129","author":"Asano","year":"2017","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.imlet.2022.09.004_bib0002","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/j.ijrobp.2020.12.004","article-title":"Effect of Interleukin-7 on radiation-induced lymphopenia and its antitumor effects in a mouse model[J]","volume":"109","author":"Byun","year":"2021","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.imlet.2022.09.004_bib0003","doi-asserted-by":"crossref","first-page":"547","DOI":"10.3389\/fimmu.2018.00547","article-title":"Spontaneous T cell proliferation: a physiologic process to create and maintain homeostatic balance and diversity of the immune system[J]","volume":"9","author":"Min","year":"2018","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.imlet.2022.09.004_bib0004","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1111\/ajt.14309","article-title":"Depletion-resistant CD4 T cells enhance thymopoiesis during lymphopenia[J]","volume":"17","author":"Ayasoufi","year":"2017","journal-title":"Am. J. Transplant"},{"issue":"1","key":"10.1016\/j.imlet.2022.09.004_bib0005","first-page":"93","article-title":"[Immune checkpoint inhibitors. A breakthrough in cancer therapy][J]","volume":"150","author":"Cardenas-Oyarzo","year":"2022","journal-title":"Rev. Med. Chil."},{"issue":"8","key":"10.1016\/j.imlet.2022.09.004_bib0006","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s00018-022-04431-x","article-title":"Generation, secretion and degradation of cancer immunotherapy target PD-L1[J]","volume":"79","author":"Shen","year":"2022","journal-title":"Cell Mol. Life Sci."},{"issue":"6121","key":"10.1016\/j.imlet.2022.09.004_bib0007","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1126\/science.1231143","article-title":"Multiplex genome engineering using CRISPR\/Cas systems[J]","volume":"339","author":"Cong","year":"2013","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.imlet.2022.09.004_bib0008","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/s41598-017-00462-8","article-title":"CRISPR\/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells[J]","volume":"7","author":"Rupp","year":"2017","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.imlet.2022.09.004_bib0009","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1249558","article-title":"CRISPR-Cas9-mediated disruption of PD-1 on human T cells for adoptive cellular therapies of EBV positive gastric cancer[J]","volume":"6","author":"Su","year":"2017","journal-title":"Oncoimmunology"},{"issue":"3","key":"10.1016\/j.imlet.2022.09.004_bib0010","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00262-018-2281-2","article-title":"CRISPR\/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions[J]","volume":"68","author":"Hu","year":"2019","journal-title":"Cancer Immunol. Immunother."},{"issue":"11","key":"10.1016\/j.imlet.2022.09.004_bib0011","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/s41419-020-03187-1","article-title":"Engineering of alpha-PD-1 antibody-expressing long-lived plasma cells by CRISPR\/Cas9-mediated targeted gene integration[J]","volume":"11","author":"Luo","year":"2020","journal-title":"Cell Death Dis."},{"issue":"24","key":"10.1016\/j.imlet.2022.09.004_bib0012","doi-asserted-by":"crossref","first-page":"7469","DOI":"10.1158\/1078-0432.CCR-07-1163","article-title":"Allogeneic MHC gene transfer enhances an effective antitumor immunity in the early period of autologous hematopoietic stem cell transplantation[J]","volume":"13","author":"Kobayashi","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.imlet.2022.09.004_bib0013","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.hoc.2017.06.005","article-title":"Gene modified T Cell therapies for hematological malignancies[J]","volume":"31","author":"Abramowski-Mock","year":"2017","journal-title":"Hematol.Oncol. Clin. North Am."},{"issue":"6","key":"10.1016\/j.imlet.2022.09.004_bib0014","first-page":"716","article-title":"[Adoptive therapy with TCR gene-modified T cells for hematological malignancies and solid tumors][J]","volume":"60","author":"Ikeda","year":"2019","journal-title":"Rinsho Ketsueki"},{"issue":"11","key":"10.1016\/j.imlet.2022.09.004_bib0015","doi-asserted-by":"crossref","DOI":"10.1002\/adbi.201900253","article-title":"Improving cancer immunotherapy with CRISPR-based technology[J]","volume":"4","author":"Li","year":"2020","journal-title":"Adv. Biosyst."},{"issue":"4","key":"10.1016\/j.imlet.2022.09.004_bib0016","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1097\/HP.0000000000001451","article-title":"The natural history of acute radiation-induced H-ARS and concomitant multi-organ injury in the non-human primate: the MCART experience[J]","volume":"121","author":"Farese","year":"2021","journal-title":"Health Phys."},{"issue":"2","key":"10.1016\/j.imlet.2022.09.004_bib0017","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/cmi.2009.117","article-title":"Enhancement of antitumor immunity by low-dose total body irradiationis associated with selectively decreasing the proportion and number of T regulatory cells[J]","volume":"7","author":"Liu","year":"2010","journal-title":"Cell Mol. Immunol."},{"issue":"3","key":"10.1016\/j.imlet.2022.09.004_bib0018","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s11060-017-2678-3","article-title":"Pre-treatment lymphopenia and indication of tumor-induced systemic immunosuppression in medulloblastoma[J]","volume":"136","author":"Patel","year":"2018","journal-title":"J. Neurooncol."},{"issue":"7-8","key":"10.1016\/j.imlet.2022.09.004_bib0019","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.bulcan.2020.04.009","article-title":"[Mechanisms of radiation-induced lymphopenia and therapeutic impact][J]","volume":"107","author":"Cesaire","year":"2020","journal-title":"Bull Cancer"},{"issue":"11","key":"10.1016\/j.imlet.2022.09.004_bib0020","first-page":"1021","article-title":"Lymphopenia and clinical outcomes in patients with residual nodal disease after neoadjuvant chemotherapy for breast cancer[J]","volume":"31","author":"Gutkin","year":"2020","journal-title":"Cancer Causes Control"}],"container-title":["Immunology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165247822001298?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165247822001298?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T07:40:44Z","timestamp":1759045244000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165247822001298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":20,"alternative-id":["S0165247822001298"],"URL":"https:\/\/doi.org\/10.1016\/j.imlet.2022.09.004","relation":{},"ISSN":["0165-2478"],"issn-type":[{"value":"0165-2478","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lymphopenic condition enhanced the antitumor immunity of PD-1-knockout T cells mediated by CRISPR\/Cas9 system in malignant melanoma","name":"articletitle","label":"Article Title"},{"value":"Immunology Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.imlet.2022.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier B.V. on behalf of European Federation of Immunological Societies.","name":"copyright","label":"Copyright"}]}}